These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 32606807)
1. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. Makita S; Maruyama D; Tobinai K Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807 [TBL] [Abstract][Full Text] [Related]
2. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure. Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912 [TBL] [Abstract][Full Text] [Related]
4. Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant. Goto A; Fujita C; Horiguchi H; Iyama S; Kobune M Cureus; 2024 Mar; 16(3):e57291. PubMed ID: 38690456 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910 [TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220 [TBL] [Abstract][Full Text] [Related]
7. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma]. Maruyama D Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053 [TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
9. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Siddiqi T; Thomas SH; Chen R Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256 [TBL] [Abstract][Full Text] [Related]
10. The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19. Rajabto W; Chandika V; Harahap AS; Ham MF Int Med Case Rep J; 2022; 15():269-273. PubMed ID: 35677855 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma. Nikolaenko L; Nademanee A Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451 [TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163 [TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649 [TBL] [Abstract][Full Text] [Related]
15. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123 [TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ; Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416 [TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564 [TBL] [Abstract][Full Text] [Related]
18. Sequencing novel agents in the treatment of classical Hodgkin lymphoma. Ferhanoglu B; Ozbalak M Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182 [TBL] [Abstract][Full Text] [Related]